Key facts
- AMR Bio’s last known valuation is $1.7M (Sep 2025).
- It has raised $980K; the latest was Early Stage VC ($980K) in Sep 2025.
- Notable investors include EMV Capital (Acquired).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AMR Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for AMR Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AMR Bio
Developer of anti infective pharmaceutical candidates intended for infection prevention. The company uses a proprietary ultra rapid antibacterial mechanism and supports preventative and dermal formulations, enabling healthcare providers to reduce post surgical staphylococcal infections and address antimicrobial resistance.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2025
- Website
- amr-bio.com/
- Ownership
- Privately Held (backing)
AMR Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AMR Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AMR Bio in its N-PORT filings yet. We sweep new filings monthly.